LearnGlossaryMarketStocksSuperinvestorsSign in

SOPH

SOPHiA GENETICS S.A.

Healthcare · $694M market cap

Verdict

We can't put a fair value on SOPH right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-38.3% a year✗
Sales growth20.8% a year✓
Free cash flow growth—?
Return on invested capital-51.8%✗

Follow SOPH

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds SOPH. In Q1 2026, 1 sold out. Who we track

Chuck Akre

Akre Capital Management · as of Q2 2026

$21.5M

3,719,140 shares

Moves in Q1 2026

Sold out: Polen Capital Management

Insider activity

Since Sep 8, 2026: no open-market purchases and 1 sale worth $51K. Why purchases matter

Sales

HIBBS KATHY L

director · 2026-09-08

Sold

$51K

About SOPHiA GENETICS S.A.

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals…

Medical - Healthcare Information Services

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works